Quick Answer
NEUROCRINE BIOSCIENCES INC reported Diluted EPS of $4.67 per share for fiscal year 2025.
NEUROCRINE BIOSCIENCES INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $4.67 | +41.9% |
| 2024 | $3.29 | +33.2% |
| 2023 | $2.47 | +58.3% |
| 2022 | $1.56 | +69.6% |
| 2021 | $0.92 | -77.9% |
| 2020 | $4.16 | +966.7% |
| 2019 | $0.39 | +77.3% |
| 2018 | $0.22 | +113.6% |
| 2017 | -$1.62 | +0.6% |
| 2016 | -$1.63 | -55.2% |
| 2015 | -$1.05 | -29.6% |
| 2014 | -$0.81 | -17.4% |
| 2013 | -$0.69 | -962.5% |
| 2012 | $0.08 | -88.1% |
| 2011 | $0.67 | +546.7% |
| 2010 | -$0.15 | +88.5% |
| 2009 | -$1.30 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.04 | +64.5% | +92.5% |
| June 30, 2025 | $1.06 | +68.3% | +1225.0% |
| March 31, 2025 | $0.08 | -81.0% | -93.5% |
| September 30, 2024 | $1.24 | +51.2% | +96.8% |
| June 30, 2024 | $0.63 | -33.7% | +50.0% |
| March 31, 2024 | $0.42 | +153.2% | -48.8% |
| September 30, 2023 | $0.82 | +18.8% | -13.7% |
| June 30, 2023 | $0.95 | +627.8% | +220.3% |
- NEUROCRINE BIOSCIENCES INC showed an increase of +41.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2009–2025 period, NEUROCRINE BIOSCIENCES INC’s diluted eps has grown by 459.2% (from $1.30 per share (loss) to $4.67 per share).
- The most recent figure is from NEUROCRINE BIOSCIENCES INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: